436 related articles for article (PubMed ID: 30122651)
1. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab.
Suzaki I; Kimura Y; Tanaka A; Hirano K; Ishibashi A; Mizuyoshi T; Ando I; Kitajima T; Watanabe S; Hinohira Y; Kobayashi H
Auris Nasus Larynx; 2019 Feb; 46(1):141-146. PubMed ID: 29909018
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma.
Iino Y; Sekine Y; Yoshida S; Kikuchi S
Auris Nasus Larynx; 2021 Jun; 48(3):353-360. PubMed ID: 32943257
[TBL] [Abstract][Full Text] [Related]
4. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media.
Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
Acta Otolaryngol; 2014 Apr; 134(4):366-72. PubMed ID: 24628335
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of anti-IgE therapy for eosinophilic otitis media.
Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
Otol Neurotol; 2012 Sep; 33(7):1218-24. PubMed ID: 22825324
[TBL] [Abstract][Full Text] [Related]
6. Bone conduction hearing level in patients with eosinophilic otitis media associated with bronchial asthma.
Iino Y; Usubuchi H; Kodama K; Takizawa K; Kanazawa T; Ohta Y
Otol Neurotol; 2008 Oct; 29(7):949-52. PubMed ID: 18758390
[TBL] [Abstract][Full Text] [Related]
7. Risk factors associated with severity of eosinophilic otitis media.
Kanazawa H; Yoshida N; Yamamoto H; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Iino Y
Auris Nasus Larynx; 2014 Dec; 41(6):513-7. PubMed ID: 25199747
[TBL] [Abstract][Full Text] [Related]
8. Eosinophil chemoattractants in the middle ear of patients with eosinophilic otitis media.
Iino Y; Kakizaki K; Katano H; Saigusa H; Kanegasaki S
Clin Exp Allergy; 2005 Oct; 35(10):1370-6. PubMed ID: 16238798
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
10. New Insights into Eosinophilic Otitis Media.
Kanazawa H; Yoshida N; Iino Y
Curr Allergy Asthma Rep; 2015 Dec; 15(12):76. PubMed ID: 26546407
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease.
Iino Y; Tomioka-Matsutani S; Matsubara A; Nakagawa T; Nonaka M
Auris Nasus Larynx; 2011 Aug; 38(4):456-61. PubMed ID: 21251776
[TBL] [Abstract][Full Text] [Related]
12. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
[TBL] [Abstract][Full Text] [Related]
13. Use of IL-5 Inhibitor Benralizumab as a Novel Therapy for Eosinophilic Otitis Media: Clinical Capsule and Review of Literature.
Chow K; Cosetti MK
Otol Neurotol; 2020 Feb; 41(2):e238-e240. PubMed ID: 31923159
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
15. Eosinophilic inflammation in the middle ear induces deterioration of bone-conduction hearing level in patients with eosinophilic otitis media.
Iino Y; Usubuchi H; Kodama K; Kanazawa H; Takizawa K; Kanazawa T; Ohta Y
Otol Neurotol; 2010 Jan; 31(1):100-4. PubMed ID: 19816234
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilic otitis media: a new middle ear disease entity.
Iino Y
Curr Allergy Asthma Rep; 2008 Nov; 8(6):525-30. PubMed ID: 18940145
[TBL] [Abstract][Full Text] [Related]
17. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of instillation of triamcinolone acetonide into the middle ear for eosinophilic otitis media associated with bronchial asthma.
Iino Y; Nagamine H; Kakizaki K; Komiya T; Katano H; Saruya S; Kodera K
Ann Allergy Asthma Immunol; 2006 Dec; 97(6):761-6. PubMed ID: 17201235
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilic otitis media; state-of-the-art diagnosis and treatment.
Iino Y
Auris Nasus Larynx; 2023 Aug; 50(4):479-489. PubMed ID: 36528403
[TBL] [Abstract][Full Text] [Related]
20. [The eosinophilic otitis media's research progress].
Liu Y; Zhang Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Sep; 29(17):1577-80. PubMed ID: 26647553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]